EntryPoint Capital’s Applied Therapeutics APLT Stock Holding History

EntryPoint Capital’s Portfolio APLT Stock Details APLT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-40,070	Closed	-$272K	–	878
2024 Q1	$272K	Buy	+40,070	New	+$180K	0.24%	40

Other funds holding APLT

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EntryPoint Capital's APLT Position: Q2 2024 in Review

EntryPoint Capital sold out of Applied Therapeutics (APLT) in Q2 2024, closing a stake of 40,070 shares — an estimated $272K sold.

EntryPoint Capital first reported a position in APLT in Q1 2024 and held it in 1 quarter. The position peaked at $272K in Q1 2024. 94 funds tracked by Wall St. Rank hold APLT as of Q2 2024.

EntryPoint Capital reported no remaining Applied Therapeutics position as of Q2 2024 after selling out during the quarter.
EntryPoint Capital sold 40,070 Applied Therapeutics shares in Q2 2024, an estimated $272K.
EntryPoint Capital first reported a position in Applied Therapeutics in Q1 2024 and held it in 1 quarter.
EntryPoint Capital's Applied Therapeutics position peaked at $272K in Q1 2024.
94 funds tracked by Wall St. Rank held Applied Therapeutics as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.